EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

被引：0
作者：
Erik Thunnissen
Lukas Bubendorf
Manfred Dietel
Göran Elmberger
Keith Kerr
Fernando Lopez-Rios
Holger Moch
Wlodzimierz Olszewski
Patrick Pauwels
Frédérique Penault-Llorca
Giulio Rossi
机构：
[1] VU University Medical Centre,Department of Pathology
[2] University Hospital Basel,Institute for Pathology
[3] Charité,Institute for Pathology
[4] Solna,Department of Pathology
[5] Karolinska University Hospital,Department of Pathology
[6] Aberdeen University Medical School,Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal
[7] Hospital Universitario Sanchinarro,Institute for Surgical Pathology
[8] Universitätsspital Zurich,Department of Pathology
[9] Maria Sklodowska-Curie Institute of Oncology,Department of Pathology
[10] Department of Pathology,Sezione di Anatomia Patologica
[11] Antwerp University Hospital,undefined
[12] Centre Jean Perrin,undefined
[13] Azienda Policlinico di Modena,undefined
来源：
Virchows Archiv | 2012年 / 461卷
关键词：
Anaplastic lymphoma kinase; Rearrangement; Crizotinib; Algorithm; Guidelines; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
引用
收藏
页码：245 / 257
页数：12
相关论文
共 655 条
  • [1] Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90
  • [2] Bray F(2012)Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations Eur Respir J 39 9-28
  • [3] Center MM(2011)Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities Ther Adv Med Oncol 3 113-125
  • [4] Ferlay J(2010)The path to personalized medicine N Engl J Med 363 301-304
  • [5] Ward E(2009)EML4-ALK: honing in on a new target in non-small-cell lung cancer J Clin Oncol 27 4232-4235
  • [6] Forman D(2011)Novel therapeutic targets in non-small cell lung cancer J Thorac Oncol 6 1601-1612
  • [7] Berghmans T(2012)RET, ROS1 and ALK fusions in lung cancer Nat Med 18 378-381
  • [8] Pasleau F(2012)KIF5B-RET fusions in lung adenocarcinoma Nat Med 18 375-377
  • [9] Paesmans M(2012)A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Genome Res 22 436-445
  • [10] Bonduelle Y(2007)Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561-566
12345678910